ReviewDrugs2022
Ocrelizumab: A Review in Multiple Sclerosis.
Review in Drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 124 citations in OpenAlex.
- Comparative efficacy and safety of ocrelizumab in relapsing-remitting and primary progressive multiple sclerosis: A systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Exploring autoimmune endocrine diseases induced by monoclonal antibodies used as multiple sclerosis pharmacotherapy: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2025Pooled it
- Treatment effects of cladribine tablets on data-driven patterns of regional grey matter atrophy in multiple sclerosis.Multiple sclerosis (Houndmills, Basingstoke, England) · 2025Trial
- Pharmacokinetic-Pharmacodynamic Modelling of Repeated Ocrelizumab Dosing in Relapsing-Remitting Multiple Sclerosis.Clinical pharmacokinetics · 2026Observational
- B-cell targeting strategies for the treatment of multiple sclerosis: from non-cellular therapies to CAR-engineered cell therapies.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Article
- Efficacy and Safety of Patients With Relapsing Multiple Sclerosis Switching to Ocrelizumab Due to Suboptimal Treatment Response: Results of the 4-Year CASTING-LIBERTO Trial.European journal of neurology · 2026Article
- B Cells and B Cell Depletion in Autoimmunity and Atherosclerosis.Life (Basel, Switzerland) · 2026Review
- Adjunctive strategies in multiple sclerosis treatment: non-pharmacological approaches and their potential clinical implications.Journal of translational medicine · 2026Review
- Comic: explainable drug repurposing via contrastive masking for interpretable connections.BMC bioinformatics · 2026Article
- Design and Synthesis of MBP-Fc-Bifunctional Peptide Inhibitor to ImproveMolecular pharmaceutics · 2026Article
- Route of Administration Determines the Immunosuppressive Mechanism of Bifunctional Peptide Inhibitors in a Mouse EAE Model.Molecular pharmaceutics · 2026Article
- Pharmacodynamics and Pharmacokinetics of Ublituximab Compared with Other Anti-CD20 Monoclonal Antibodies for Multiple Sclerosis Treatment.Current neuropharmacology · 2026Review
- Sex and gender as contributors to brain pathophysiology, clinical course, and therapeutic response in multiple sclerosis.Frontiers in behavioral neuroscience · 2026Review
- Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.Case reports in medicine · 2026Article
- Overcoming Synthetic Challenges and Evaluating in Vivo Efficacy of the MOG-Fc-Bifunctional Peptide Inhibitor for EAE in Mice.Bioconjugate chemistry · 2025Article
- Relation of Visual Function, Retinal Thickness by Optical Coherence Tomography, and MRI Brain Volume in Pediatric-Onset Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2025Article
- Altered miR-203a and miR-3622b-5p expressions in multiple sclerosis: novel correlations with apoptotic gene expression profiles.Molecular biology reports · 2025Article
- Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025Article
- Primary Progressive Multiple Sclerosis: New Therapeutic Approaches.Neuropsychopharmacology reports · 2025Review
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ocrelizumab (Ocrevus
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.